Michael F. Berger
YOU?
Author Swipe
View article: Intelligent surgical drainage - digitizing the analysis of drainage fluid in patients with surgical drains
Intelligent surgical drainage - digitizing the analysis of drainage fluid in patients with surgical drains Open
Surgical drains are essential in post-operative care, where timely removal is critical to prevent complications. Early removal can result in seromas and hematomas, while delayed removal may lead to infections. Traditional manual analysis o…
View article: Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma Open
View article: Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)
Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance) Open
We looked at the link between tumor DNA present in blood and outcomes after chemotherapy for patients with advanced bladder cancer. Higher amounts of tumor DNA in blood and mutations in specific cancer genes were linked to worse survival. …
View article: Continuous spectroscopic monitoring of urinary catheter output: advancements and clinical implications
Continuous spectroscopic monitoring of urinary catheter output: advancements and clinical implications Open
View article: Data from Cancer-Causative Mutations Occurring in Early Embryogenesis
Data from Cancer-Causative Mutations Occurring in Early Embryogenesis Open
Mosaic mutations in normal tissues can occur early in embryogenesis and be associated with hereditary cancer syndromes when affecting cancer susceptibility genes (CSG). Their contribution to apparently sporadic cancers is currently unknown…
View article: Supplementary Data from Cancer-Causative Mutations Occurring in Early Embryogenesis
Supplementary Data from Cancer-Causative Mutations Occurring in Early Embryogenesis Open
Supplementary Data from Cancer-Causative Mutations Occurring in Early Embryogenesis
View article: Data from Cancer-Causative Mutations Occurring in Early Embryogenesis
Data from Cancer-Causative Mutations Occurring in Early Embryogenesis Open
Mosaic mutations in normal tissues can occur early in embryogenesis and be associated with hereditary cancer syndromes when affecting cancer susceptibility genes (CSG). Their contribution to apparently sporadic cancers is currently unknown…
View article: Supplementary Materials from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy
Supplementary Materials from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy Open
PDF file - 321KB, A detailed description of additional methods utilized (and associated references) for sequencing and analysis as well as an explanatory note regarding the TM pathway in yeast.
View article: Supplementary Figures S1 - S2 from An Acquired <i>HER2</i> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
Supplementary Figures S1 - S2 from An Acquired <i>HER2</i> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer Open
Supplementary Figure S1. HER2L869R and HER3E928G cooperate to drive ERBB signaling output. Supplementary Figure S2. MG132 treatment restores expression of HER2T798I.
View article: Table S1-4 from Accelerating Discovery of Functional Mutant Alleles in Cancer
Table S1-4 from Accelerating Discovery of Functional Mutant Alleles in Cancer Open
Supplementary Tables 1-4
View article: Data from An Acquired <i>HER2</i> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
Data from An Acquired <i>HER2</i> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer Open
We report a HER2T798I gatekeeper mutation in a patient with HER2L869R-mutant breast cancer with acquired resistance to neratinib. Laboratory studies suggested that HER2L869R is a nerati…
View article: Data from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy
Data from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy Open
Metastatic solid tumors are almost invariably fatal. Patients with disseminated small-cell cancers have a particularly unfavorable prognosis, with most succumbing to their disease within two years. Here, we report on the genetic and functi…
View article: Supplementary Table 1 from Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping
Supplementary Table 1 from Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping Open
nanoString probe sequences for MET exons 3, 4, 14, 20, and 21.
View article: Supplementary Figure 4 from Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies
Supplementary Figure 4 from Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies Open
PDF file 338K, Phospho-flow data
View article: Supplementary Fig 4 from HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers
Supplementary Fig 4 from HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers Open
Supplementary Fig 4
View article: Supplemental Methods, Supplemental Tables 1-2, Supplemental Figures 1-4 from AACR Project GENIE: Powering Precision Medicine through an International Consortium
Supplemental Methods, Supplemental Tables 1-2, Supplemental Figures 1-4 from AACR Project GENIE: Powering Precision Medicine through an International Consortium Open
Supplemental Methods. Supplemental Table 1: ââ,¬â€¹Genomic Data Characterization by Center. Supplemental Table 2: ââ,¬â€¹Gene Panels Submitted by Each Center. Figure S1: Number of putative germline SNPs per sample, before and after unifo…
View article: Figure S1-7 from Accelerating Discovery of Functional Mutant Alleles in Cancer
Figure S1-7 from Accelerating Discovery of Functional Mutant Alleles in Cancer Open
Supplementary Figures 1-7
View article: Supplementary Figures S1 - S2 from An Acquired <i>HER2</i> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
Supplementary Figures S1 - S2 from An Acquired <i>HER2</i> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer Open
Supplementary Figure S1. HER2L869R and HER3E928G cooperate to drive ERBB signaling output. Supplementary Figure S2. MG132 treatment restores expression of HER2T798I.
View article: Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
Additional results for dual probe EGFR and ERBB2 FISH from Patients 9, 30 and 32.
View article: Supplementary Figure 3 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Supplementary Figure 3 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies Open
Patient 2 Concurrent EGFR and KRAS mutations in a patient identified by MSK-IMPACT
View article: Supplementary Figure Legends from Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping
Supplementary Figure Legends from Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping Open
Supplementary Figure Legends
View article: Supplementary Methods, Figure Legends, Tables S1 - S4 from An Acquired <i>HER2</i> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
Supplementary Methods, Figure Legends, Tables S1 - S4 from An Acquired <i>HER2</i> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer Open
Supplementary Table S1. Summary of mutations identified by FoundationOne profiling of the original, pre-neratinib skin metastasis. Supplementary Table S2. Frequency of HER2L869R and HER2T798I mutations. Supplementary Table S3. Sequencing o…
View article: Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
CONSORT diagram
View article: Supplementary Tables and Legend from Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies
Supplementary Tables and Legend from Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies Open
PDF file 103K, Supplementary tables and supplementary figure legends
View article: Supplementary Fig 4 from HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers
Supplementary Fig 4 from HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers Open
Supplementary Fig 4
View article: Supplementary Tables 2 - 6 from Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases
Supplementary Tables 2 - 6 from Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases Open
Supplementary Table 2. Frequency of selected genes in SQ-MAP vs. TCGA. Supplementary Table 3. Clinical characteristics of patients with resected brain metastases. Supplementary Table 4. Genes exhibiting clonal evolution from primary lung t…
View article: Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
Additional results for dual probe EGFR and ERBB2 FISH from Patients 9, 30 and 32.
View article: Supplementary Figures 1-3 from High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Supplementary Figures 1-3 from High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing Open
PDF file - 325K
View article: Supplementary Appendix from High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Supplementary Appendix from High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing Open
XLS file - 3.7MB
View article: Supplementary Figures 1 - 2 from Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases
Supplementary Figures 1 - 2 from Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases Open
Supplementary Figure 1. Copy number pattern in paired lung cancer primaries and brain metastases from patients PP1, PP2, and PP4. Red, blue, and white indicate gain, loss, neutral states, respectively. The total number of shared cytobands …